PGIMER’s Transfusion Medicine Department Collects 117 Units of Blood, Sets Up Next Donation Camp at Glenmark Pharmaceuticals, Nalagarh on May 15
The Department of Transfusion Medicine at PGIMER, Chandigarh, recently conducted two blood donation camps in the city, with the goal of ensuring an adequate blood supply for patients in need. The first camp was held on May 14, 2025, at the Community Center in Manimajra, in association with the Chandigarh Municipal Corporation. Under the leadership of Dr. Suchet Sachdev, a total of 42 blood units were collected from volunteer donors.
A second camp was also held on the same day at the Community Centre in Sector 28, Chandigarh, in association with the Chandigarh Municipal Corporation. This camp, led by Dr. Ekta Paramjit, collected 75 blood units. The Department of Transfusion Medicine expressed its gratitude to all the donors who participated, noting that their contributions will help cater to the needs of critically ill patients in the institute.
The blood donation camps are part of the department’s ongoing efforts to ensure a steady supply of blood and blood components for patients. The donated blood will be used to support the treatment of patients at PGIMER, Chandigarh. The department is committed to continuing its life-saving mission and has scheduled another blood donation camp for May 15, 2025, in association with Glenmark Pharmaceuticals Ltd. The camp will be held at the company’s premises in Nalagarh, starting at 10:00 a.m.
Individuals interested in participating in the upcoming camp can contact the Senior Resident from PGIMER or Mr. Yash Pal for more information. The department encourages all eligible individuals to come forward and donate blood, as their contributions can help save lives. By supporting blood donation camps like these, individuals can make a significant difference in the lives of patients in need of blood transfusions. The Department of Transfusion Medicine is dedicated to continuing its efforts to ensure a safe and adequate blood supply, and the support of volunteer donors is crucial to achieving this goal.
Dr. Rooma Sinha from Apollo achieves milestone of over 1,000 robotic surgeries for benign gynecological conditions.
Dr. Rooma Sinha, a renowned gynecologist at Apollo Hospitals, has achieved a remarkable milestone by completing over 1,000 robotic surgeries for benign gynecological conditions. This feat is a testament to her exceptional skills and expertise in the field of robotic surgery.
Benign gynecological conditions, such as fibroids, endometriosis, and pelvic organ prolapse, can have a significant impact on a woman’s quality of life. Traditional open surgery or laparoscopic surgery can be effective in treating these conditions, but they often come with a higher risk of complications, longer hospital stays, and more post-operative pain.
Robotic surgery, on the other hand, offers a minimally invasive alternative that can reduce the risk of complications and promote faster recovery times. The robotic system provides surgeons with high-definition, 3D visualization and precise instrumentation, allowing for more accurate dissection and suturing.
Dr. Sinha’s extensive experience with robotic surgery has enabled her to develop a high level of proficiency in performing complex procedures with ease. Her patients have benefited from reduced blood loss, less post-operative pain, and shorter hospital stays.
Some of the key benefits of robotic surgery for benign gynecological conditions include minimal scarring, reduced risk of infection, and faster return to normal activities. Additionally, robotic surgery can help preserve fertility in women of childbearing age, making it an attractive option for those who wish to have children in the future.
Dr. Sinha’s achievement is not only a testament to her individual skill but also reflects the advancement of medical technology and the commitment of Apollo Hospitals to providing cutting-edge care to its patients. The hospital’s investment in robotic surgery technology has enabled surgeons like Dr. Sinha to push the boundaries of what is possible in the field of gynecology.
As robotic surgery continues to evolve, it is likely that we will see even more innovative applications of this technology in the future. For now, Dr. Sinha’s milestone serves as a reminder of the importance of staying at the forefront of medical innovation and the impact that skilled surgeons can have on the lives of their patients.
In conclusion, Dr. Rooma Sinha’s completion of over 1,000 robotic surgeries for benign gynecological conditions is a significant achievement that highlights the benefits of robotic surgery for women’s health. Her expertise and dedication to her patients have made a tangible difference in their lives, and her work serves as a model for other surgeons and medical institutions to follow.
NIVEA India names Akshay Kawale as new Business Unit Head – Derma
NIVEA India has appointed Akshay Kawale as the Business Unit Head of its Derma division, effective April 3, 2025. Kawale brings 16 years of experience in the industry, having worked with prominent organizations such as Glenmark Pharmaceuticals, Abbott, GSK, and L’Oréal. Most recently, he served as Business Head of Cosmetology at Glenmark Pharmaceuticals, where he played a key role in developing and scaling skincare business strategies.
In his new role at NIVEA, Kawale will be responsible for leading the Derma business unit for Eucerin, a brand known for its dermatological expertise and trust. Geetika Mehta, Managing Director of NIVEA India, expressed her delight at Kawale’s appointment, citing his deep understanding of the derma category and ability to drive business transformation as key assets in expanding Eucerin’s presence in India.
Mehta also highlighted Kawale’s consumer-first approach and strategic acumen as essential qualities to drive the next phase of growth for the brand. Kawale himself expressed his excitement to join Eucerin, a brand he admires for its global reputation in dermatological expertise and trust. He looks forward to contributing to the brand’s growth in India while staying true to its values of skincare science and care.
Kawale’s appointment is seen as a significant move by NIVEA India to strengthen its position in the derma category, particularly with the Eucerin brand. With his extensive experience and expertise, Kawale is expected to play a key role in driving business growth and expansion for Eucerin in India. The company is confident that Kawale’s leadership will help take the brand to new heights, building on its reputation for dermatological expertise and trust. Overall, the appointment of Akshay Kawale as Business Unit Head of Derma is a strategic move by NIVEA India to drive growth and expansion in the Indian market.
Nomura Warns: Trump’s Drug Pricing Order Could Have Significant Impact on Sun Pharma
The pharmaceutical sector is facing uncertainty after US President Donald Trump signed an executive order on May 12, requiring US drug companies to align their prices with those in other developed countries. This move could have a significant negative impact on the revenues and earnings of pharmaceutical companies, particularly those with a significant US footprint. Japanese brokerage firm Nomura believes that this order is “negative for the specialty/branded segment and a mixed bag for generics.”
The order mandates that pharmaceutical companies align their prices with those in other developed countries, where prices are often 2-5 times lower. This could lead to a significant reduction in prices in the US, which could impact the revenues of companies like Sun Pharma, which has a significant presence in the US market. Sun Pharma’s largest product, Ilumya, is particularly vulnerable to price alignment mandates, as its listed price in the US is approximately four times higher than in other developed countries.
The executive order also has implications for the generics market. While it may lower the addressable market for generics and biosimilars, it could also lead to better price realization and faster penetration of biosimilars if the trade channel’s dominance is weakened. However, commoditized generics are unlikely to see much impact, as their prices are already deeply discounted due to market competition.
The order instructs the administration to communicate targeted price levels to pharmaceutical companies within 30 days, and failure to comply could result in actions such as liberalizing drug imports and restricting exports. Trump has stated that US citizens pay massively higher prices for the same drugs as other countries, and that this order aims to address this issue.
However, Nomura believes that there are hurdles in the implementation of this order, as a similar executive move in 2020 faced multiple legal setbacks and was eventually blocked by US courts. The order’s impact on the pharmaceutical sector will depend on its implementation, and companies with a significant US presence, such as Sun Pharma, will be closely watching the developments. Overall, the executive order has introduced significant uncertainty in the pharmaceutical sector, and its impact will be closely monitored by investors and industry stakeholders.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.